SM
EGRX

Sabby Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Sabby Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,000
Closed -$405K – 336
2016
Q1 		$405K Buy
+10,000
New +$634K 0.02% 223

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Sabby Management's EGRX Position: Q2 2016 in Review

Sabby Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2016, closing a stake of 10,000 shares — an estimated $405K sold.

Sabby Management first reported a position in EGRX in Q1 2016 and held it in 1 quarter. The position peaked at $405K in Q1 2016. 116 funds tracked by Wall St. Rank hold EGRX as of Q2 2016.

  • Sabby Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Sabby Management sold 10,000 Eagle Pharmaceuticals, Inc. shares in Q2 2016, an estimated $405K.
  • Sabby Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • Sabby Management's Eagle Pharmaceuticals, Inc. position peaked at $405K in Q1 2016.
  • 116 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.